Wczytywanie kursów wyceny...
Prognoza
Nie mamy danych analityków dla tej spółki.
Wiadomości Przejdź do aktualności
Innocan Pharma plans listing on NYSE American by Jan. 30
Innocan Pharma expects to be listed on the NYSE American by January 30, 2026, subject to approval and compliance with exchange rules. The company is simultaneously considering, depending on market conditions and regulatory approval, a concurrent offering of securities; details will be provided in SEC and SEDAR+ filings. Common shares are expected to continue trading on the OTCQB until the close of trading on or about January 29; trading on the CSE under the ticker INNO will remain in place. Innocan reports a market capitalization of roughly $19.72 million, more cash than debt, a current ratio of 3.72, and a share price trading near its 52-week low. » Więcej na de.investing.com
InnoCan Pharma reports Q3 EPS loss of CAD 0.49 and 20% revenue decline
For the quarter ended September 30, 2025, InnoCan Pharma reported an EPS loss of CAD 0.49 per share (year-ago: -CAD 0.090). Revenue fell to CAD 9.4 million from CAD 11.8 million in the year-ago quarter, a decline of 20.07%. The figures were presented at the financial conference for the quarter ended on November 26, 2025. » Więcej na finanzen.net
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 4,48 mln | 24,57% |
| Zysk brutto | 4,07 mln | 22,52% |
| Zysk netto | -29,03 tys. | 94,20% |
| EBITDA | -429,54 tys. | 427,38% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 6,41 mln € |
Liczba akcji | 4,5 mln |
Maksimum/minimum z 52 tygodni | 12,53 € - 1,30 € |
| Dywidendy | Nie |
Beta | -0,22 |
C/Z (PE Ratio) | -7,49 |
PEG (PEG Ratio) | 0,07 |
C/WK (PB Ratio) | 1,46 |
C/S (PS Ratio) | 0,30 |
Profil spółki
| Nazwa | Innocan Pharma |
| CEO | Iris Bincovich |
| Siedziba | Calgary,
ab Kanada |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Ochrona zdrowia: świadczeniodawcy i usługi |
| Pracownicy | 11 |
